CD274 and cancer: In a cohort of cancer patients treated with anti-PD-L1 therapy, a larger percentage of patients with a BMI greater than 30 kg/m2 had increased progression-free survival and overall survival compared to patients with a BMI less than 30 kg/m2 [255].